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Strengths and limitations of this study
 ► This study included a large number of healthy 
participants.
 ► The participants were prospectively followed up for 
a long duration.
 ► The self-reported questionnaires may limit reliability.
 ► The observational nature of the study limits the as-
certainment of the cause–effect relationship.
AbStrACt
Objectives Previous studies have shown that 
symptoms of sleep-disordered breathing are associated 
with metabolic derangements and vascular disease 
development. However, the relationship between snoring 
and renal function is not well investigated. The association 
between snoring and the development of incident chronic 
kidney disease (CKD) in subjects with normal renal 
function was evaluated.
Design Prospective cohort study.
Setting Ansung (rural community) and Ansan (urban 
community) cities.
Participants Community-based cohort participants aged 
40–69 years.
Methods A total of 9062 participants in the Ansung–
Ansan cohort study were prospectively followed up from 
2001 to 2014. The participants were classified into three 
groups: non-snorer, <1 day/week and ≥1 day/week. The 
main outcome was incident CKD, which was defined as an 
estimated glomerular filtration rate of <60 mL/min/1.73 m2 
during the follow-up period.
Primary outcome Incident CKD.
results The mean subject age was 52.0±8.9 years, and 
4372 (48.2%) subjects were male. The non-snorer,<1 day/
week and ≥1 day/week groups included 3493 (38.5%), 
3749 (41.4%), and 1820 (20.1%) subjects, respectively. 
Metabolic syndrome was more prevalent in the snoring 
groups than in the non-snoring group. Snoring frequency 
showed a significant positive relationship with age, 
waist:hip ratio, fasting glucose, total cholesterol (Tchol) 
and low-density lipoprotein cholesterol. During a mean 
follow-up of 8.9 years, 764 (8.4%) subjects developed 
CKD. Cox proportional hazards model analysis revealed 
that the risk of CKD development was significantly higher 
in subjects who snored ≥1 day/week than in non-snorers, 
even after adjustments for confounding factors (HR 1.23, 
95% CI 1.09 to 1.38, p<0.01).
Conclusion Snoring may increase the risk of CKD 
development in subjects with normal renal function.
IntrODuCtIOn
The prevalence of chronic kidney disease 
(CKD) is rapidly increasing worldwide 
despite blood glucose control and hyperten-
sion management, which are the main factors 
that affect renal function.1 As established 
CKD is an irreversible condition, increasing 
emphasis has been placed on detecting high-
risk patients and implementing early inter-
ventions. Therefore, identifying lifestyles and 
easy-to-detect habitual behaviours associated 
with the development of CKD is an important 
starting point of the process of reducing the 
burden associated with CKD.2
Snoring without apnoea is commonly 
considered as a mild form of obstructive 
sleep-disordered breathing. Although most 
people with obstructive sleep apnoea (OSA) 
complain of symptoms of snoring, the preva-
lence of actual OSA among snorers has been 
shown to vary.3 4 This suggests that snoring 
could occur independent of OSA. Reports 
have also proposed a possibility that several 
medical problems are related to snoring 
independent of the OSA status, suggesting 
that snoring by itself could have adverse clin-
ical implications on medical conditions.5 6 
Although snorers with OSA were not totally 
excluded, cumulative studies have also 
reported that snoring is associated with hyper-
tension, cardiovascular diseases and stroke.7–9
Several previous studies have evaluated the 
effect of OSA on renal function. However, 
the results have been mixed and inconclu-
sive.10–13 In addition, these studies evaluating 
the association of sleep-disordered breathing 
Protected by copyright.
 o
n
 Septem
ber 2, 2019 at M
edical Library / Yonsei University.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030671 on 5 August 2019. Downloaded from 
2 Lee C, et al. BMJ Open 2019;9:e030671. doi:10.1136/bmjopen-2019-030671
Open access 
Figure 1 Flow diagram of the study cohort. eGFR, estimated glomerular filtration rate.
with renal function have focused on OSA rather than 
snoring.
Therefore, in order to investigate whether snoring 
affects renal function, the relationship between self-re-
ported snoring and development of CKD was assessed 
in a prospective community-based cohort consisting of 
subjects with normal renal function. This investigation 
was based on the hypothesis that snoring may affect 
kidney function. The Korean Genome and Epidemiology 
Study (KOGES) cohort study data were used to assess this 
hypothesis since the cohort’s objectives met the purpose 
of this evaluation.
MAterIAlS AnD MethODS
Study population
Data from the Ansung–Ansan cohort study were used. 
The Ansung–Ansan cohort study is an ongoing prospec-
tive study started in 2001 as part of the KoGES. Detailed 
profile and methods concerning the development of 
the cohort have been described previously.14 In brief, 
the cohort consists of residents aged 40 to 69 years from 
Ansung (rural community) and Ansan (urban commu-
nity) city, which are located near the Korean capital of 
Seoul. Successive health examinations and surveys are 
being biennially performed from 2001. The baseline 
survey, which was carried out from 2001 to 2002, included 
10 030 participants. After excluding subjects whose base-
line estimated glomerular filtration rate (eGFR) was 
<60 mL/min/1.73 m2, those with a past history of kidney 
disease, and those with missing data, a total of 9062 
participants were included in this analysis (figure 1). The 
participants were traced until the sixth follow-up survey 
performed in 2014.
This study was carried out in accordance with the Decla-
ration of Helsinki and was approved by the institutional 
review board of the Yonsei University Health System Clin-
ical Trial Centre (4-2016-0900). All subjects were fully 
informed of the study contents, and they provided written 
informed consents for data use.
Clinical and laboratory measurements
All participants completed a comprehensive health exam-
ination and interview according to a site visit schedule. 
The health examination included evaluation of anthro-
pometric indices and the collection of biological speci-
mens for assessment.
The study participants completed interviewer-admin-
istered questionnaires that included questions on age, 
smoking and alcohol status, level of education and income, 
marital status, degree of physical activity and medical 
history. Anthropometric variables, including weight, 
abdominal girth and hips, were measured based on stan-
dard methods by skilled study workers, with the subjects 
wearing light clothing. Body mass index (BMI) was calcu-
lated as weight (kg)/height (m2). Waist circumference 
was measured in a horizontal plane, midway between the 
inferior margin of the ribs and the superior border of 
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the iliac crest. Waist:hip ratio (WHR) was calculated by 
dividing waist circumference to hip circumference. Blood 
pressure was measured by trained technicians using 
mercury sphygmomanometers (Baumanometer Standby; 
W.A. Baum Co., Copiague, NY, USA). Before blood pres-
sure measurement, the subjects were instructed to relax 
in the sitting position for at least 10 min. The mean of two 
blood pressure readings was used for data analyses.
After at least 8 hours of fasting, blood and urine samples 
were collected and delivered to a central laboratory (Seoul 
Clinical Laboratories, Seoul, Republic of Korea) within 
24 hours of sampling. Plasma was separated by centrif-
ugation (2000 rpm, 20 min, at 4°C), and biochemical 
measurements were immediately conducted. The plasma 
concentrations of glucose, Tchol, triglycerides (TGs) 
and high-density lipoprotein cholesterol (HDL-C) were 
measured enzymatically using a 747 Chemistry Analyzer 
(Hitachi, Tokyo, Japan). Low-density lipoprotein-cho-
lesterol (LDL-C) was calculated using the Friedewald 
equation.15 Serum creatinine (Scr) was measured using 
Jaffe's method with a Hitachi Automatic Analyzer 7600 
(Hitachi). eGFR was calculated using the Chronic Kidney 
Disease Epidemiology Collaboration equation: eGFR 
(mL/min/1.73 m2)=141×min (Scr/κ, 1)α×max (Scr/κ, 
1)–1.209×0.993 age (years)×1.018 (if female)×1.159 (if 
black), where κ is 0.7 for women and 0.9 for men, α is 
−0.329 for women and −0.411 for men, min indicates the 
minimum of Scr/κ or 1, and max indicates the maximum 
of Scr/κ or 1.16 Surveys inquiring on socioeconomic 
status and lifestyle were performed at baseline, while 
anthropometric measurements (blood pressure, body 
weight, height, and abdominal and hip circumference) 
and laboratory evaluations (serum Tchol, TG, HDL-C, 
blood urea nitrogen creatinine, C reactive protein, blood 
glucose, haemoglobin and haematocrit) were assessed at 
each follow-up visit. Serum albumin was accessed at base-
line only.
Sleep quality assessment
Detailed information on sleep duration, quality and 
disorders, including habitual snoring, was collected using 
a self-reported sleep quality questionnaire at baseline. 
Snoring frequency was assessed using a 5-point scale: 
never, infrequently, sometimes (one to three nights/
week), often (four or five nights/week) and almost every 
night. Individuals were grouped into snorers (snoring at 
least one night/week and snoring less than one night/
week) and non-snorers. Subjects were also asked if they 
had insomnia (yes/no), had a difficulty falling asleep 
(yes/no), woke up during the night and were unable 
to fall back to sleep (yes/no), woke up too early in the 
morning (yes/no), had irregular sleeping time (yes/no), 
had the symptoms of restless legs syndrome (yes/no) 
and had experienced periodic limb movements during 
sleep (yes/no). The self-reported answers on snoring 
were confirmed by a bed partner or a family member in 
a subset of participants. In addition, excessive daytime 
sleepiness (EDS) was assessed using the Epworth sleepi-
ness scale (ESS), with a score above 11 points indicating 
EDS.17 18
Definitions of metabolic syndrome (MetS)
Based on the modified National Cholesterol Education 
Programme Adult Treatment Panel III criteria, MetS) was 
defined as the presence of three or more of the following 
components: (1) abdominal obesity, defined as a waist 
circumference of ≥90 cm for men and ≥85 cm for women 
(following Korean-specific cut-offs for abdominal obesity, 
defined by the Korean Society of Obesity); (2) hypertri-
glyceridemia, defined as a serum TG concentration of 
≥150 mg/dL; (3) low HDL cholesterol, defined as a serum 
HDL cholesterol concentration <40 mg/dL for men and 
<50 mg/dL for women; (4) high blood pressure, defined 
as a systolic blood pressure (SBP) of ≥130 mm Hg, diastolic 
blood pressure (DBP) of ≥85 mm Hg or treatment with 
antihypertensive agents; and (5) high fasting glucose, 
defined as a fasting serum glucose level of ≥100 mg/dL or 
previously diagnosed type 2 diabetes.19 20
Study outcome
The primary endpoint was incident CKD, which was 
defined as two or more consecutive eGFR <60 mL/
min/1.73 m2 during the follow-up visits. Subjects who 
were lost to follow-up were censored at the date of the last 
examination.
Statistical analysis
Statistical analyses were performed using IBM SPSS 
software for Windows V.23.0. Continuous variables are 
presented as means and SD. The normality of the distri-
bution was analysed using the Kolomogorov-Smirnov 
test. Variables not normally distributed were expressed 
as median and IQR and compared with the Jonck-
heere-Terpstra test. Categorical variables are expressed as 
frequencies and percentages. The characteristics of the 
subjects from each group were compared using one-way 
analysis of variance and two-sample t-test for continuous 
variables, or χ2 test for categorical variables. Post hoc 
analyses were done with the Scheffe method. The associ-
ations between the variables were compared using Pear-
son’s r for continuous variables and Spearman’s rho for 
categorical variables. The cumulative incidence of CKD 
by snoring frequency was assessed using Kaplan–Meier 
plots. The Cox proportional hazards model was applied 
to determine the independent association between 
snoring frequency and incident CKD after adjustment 
for confounding variables. Variables that showed statis-
tical significance in univariate regression analyses, as well 
as factors known to have clinical implication on CKD 
development, were selected for the adjustment models; 
model I included age and sex, model II included socio-
economic and lifestyle variables, and model III included 
anthropometry and laboratory features. Proportional 
hazards assumptions were confirmed using Schoenfeld 
residuals. The snoring frequency groups were considered 
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as non-time-dependent variables, while SBP, WHR, fasting 
glucose and LDL-C were treated as time-dependent vari-
ables. The results were expressed as HRs with 95% CI. 
P values less than 0.05 were considered statistically 
significant.
Patient and public involvement
Patients and the public were not involved in the design 
and conduct of this study. The results will not be dissemi-
nated to study participants.
reSultS
baseline characteristics
The baseline characteristics of the study population 
are shown in table 1. The mean age of the subjects was 
52.0±8.9 years, and 48.2% of them were male. The average 
eGFR was 93.8±13.0 mL/min/1.73 m2. Among the 5569 
(61.5%) subjects who snored, 3749 (67.3%) subjects were 
included in the snoring frequency <1 day/week group, 
and 1820 (32.7%) subjects were included in the snoring 
frequency ≥1 day/week group. More men were included 
in the snoring frequency ≥1 day/week group than in 
the non-snorer or the snoring frequency <1 day/week 
group. The WHR, SBP and DBP tended to be higher in 
subjects who snored more frequently. Individuals who 
snored more frequently were more likely to be current 
smokers or alcohol drinkers. The prevalence of comor-
bidities such as hypertension, diabetes mellitus, myocar-
dial infarction, cerebrovascular attack and MetS tended 
to be higher in subjects who snored more frequently. 
Regarding laboratory parameters, fasting glucose, Tchol, 
TG and LDL-C levels were higher, while HDL levels were 
lower in frequent snorers. Additional post hoc analyses of 
the baseline variables are shown in online supplementary 
table 1.
relationship of sleep quality with snoring frequency
The prevalence of insomnia, having difficulty falling 
asleep, waking during the night, waking too early in 
the morning, having irregular sleep time, having symp-
toms of restless legs syndrome and having periodic limb 
movements during sleep were comparable among never 
snorers and snorers. However, ESS was significantly 
higher in individuals who snored ≥1 day/week than in 
those who snored less frequently and those who never 
snored. In addition, the prevalence of EDS was higher 
in the snoring frequency ≥1 day/week group than that in 
other groups (table 2).
Development of incident CKD
During a mean follow-up duration of 8.9 years, 264 
(7.6%), 314 (8.4%), and 186 (10.2%) subjects developed 
CKD in the non-snorer group, <1 day/week snoring group 
and ≥1 day/week snoring group, respectively. A total of 
874 (9.6%) participants were lost to follow-up, and the 
number of subjects lost to follow-up in the non-snorer 
group, snoring frequency <1 day/week group and ≥1 day/
week group were 369 (10.56%), 336 (8.96%) and 169 
(9.29%), respectively. The proportion of participants 
lost to follow-up were comparable among the groups 
(p=0.06).
Impact of snoring on incident CKD
Kaplan–Meier plots showed that the time to development 
of incident CKD was significantly shorter in subjects with 
a snoring frequency of ≥1 day/week than in those with 
a snoring frequency of <1 day/week, and non-snorers 
(figure 2).
Cox proportional hazards model analyses revealed that 
the risk of development of CKD was significantly higher 
in subjects who snored ≥1 day/week than in non-snorers 
(HR 1.36, 95% CI 1.13 to 1.64, p<0.01). This finding 
was significant even after adjustments were made for 
confounding factors, including age, sex, monthly income, 
alcohol, smoking status, SBP, WHR, fasting glucose, 
calculated LDL-C (HR 1.23, 95% CI 1.09 to 1.38, p<0.01) 
(table 3). An additional analysis with adjustment for BMI 
instead of WHR revealed similar results (online supple-
mentary table 2). The proportional hazards assumption 
held reasonably for snoring frequency (online supple-
mentary figure 1).
DISCuSSIOn
In this study, the prevalence of snoring and its impact on 
renal function were investigated in subjects with normal 
kidney function. In a sleep quality questionnaire, more 
than 60% of the adult population responded that they 
were snorers. Those who snored frequently were more 
likely to be associated with metabolic abnormalities. In 
addition, frequent snorers were found to be related with 
a significantly increased risk of development of incident 
CKD.
Several recent studies have evaluated the associa-
tion between sleep parameters and CKD. An evaluation 
of Chinese adults showed that overall sleep quality was 
closely related with high risk of CKD.21 In addition, a study 
examining Chronic Renal Insufficiency Cohort partic-
ipants revealed that shorter sleep duration and greater 
sleep fragmentation were associated with lower eGFR.22 
However, in contrast with the results of the current inves-
tigation, none of these investigations found a significant 
relationship between snoring and kidney function. The 
fact that these previous reports were cross sectional eval-
uations, compared with the prospective design of this 
study, could be one of the reasons for this disparity.
Recent investigations have suggested possible asso-
ciations between OSA and decreased renal function. A 
retrospective analysis of a national health insurance data-
base showed that, compared with the general population, 
those diagnosed with sleep apnoea were at an increased 
risk of CKD.12 Similarly, another large-scale retrospective 
cohort study from Japan reported that an apnoea–hypo-
pnoea index greater than 5 was clearly associated with an 
increased OR for CKD.23 However, few of the previous 
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Table 1 Baseline characteristics of patients according to snoring frequency
Snoring frequency
P value
Non-snorer
(n=3493, men 
42.3%)
<1 day/week
(n=3749, men 
49.9%)
≥1 day/week
(n=1820, men 
56.2%)
Total
(N=9062, men 
48.2%)
Demographic data
  Age (years) 52.1±9.2 51.5±8.6 52.9±8.6 52.0±8.9 <0.01
  BMI (kg/m2) 23.7±3.0 24.7±3.1 25.7±3.2 24.5±3.1 <0.01
  Waist:hip ratio (%) 80.3±8.7 82.8±8.5 86.0±8.3 82.5±8.8 <0.01
  SBP (mm Hg) 119.6±18.3 121.0±18.0 124.1±18.0 121.1±18.2 <0.01
  DBP (mm Hg) 78.8±11.3 80.3±11.4 82.4±11.3 80.1±11.4 <0.01
  MAP (mm Hg) 92.4±13.0 93.9±13.0 96.3±12.7 93.8±13.0 <0.01
  Monthly income <$1090 1314 (37.6) 1165 (31.1) 626 (34.4) 3105 (34.3) <0.01
  Married 3421 (97.9) 3693 (98.5) 1800 (98.9) 8914 (98.4) <0.06
  Education duration >9 
years
1414 (40.5) 1744 (46.5) 838 (46.0) 3996 (44.1) <0.01
  Smoking status <0.01
  Never 2215 (63.4) 2135 (56.9) 932 (51.2) 5282 (58.3)
  Former 469 (13.4) 611 (16.3) 342 (18.8) 1422 (15.7)
  Current 809 (23.2) 1003 (26.8) 546 (30.0) 2358 (26.0)
  Alcohol status <0.01
  Never 1752 (50.2) 1633 (43.6) 746 (41.0) 4131 (45.6)
  Former 234 (6.7) 238 (6.2) 110 (6.0) 582 (6.4)
  Current 1499 (42.9) 1869 (50.0) 957 (52.6) 4325 (47.7)
Comorbidities
  HTN 359 (10.3) 577 (15.4) 360 (19.8) 1296 (14.3) <0.01
  DM 199 (5.7) 238 (6.3) 146 (8.0) 583 (6.4) <0.01
  MI 20 (0.6) 27 (0.7) 22 (1.2) 69 (0.8) 0.04
  CHF 1 (0.0) 11 (0.3) 6 (0.3) 18 (0.2) 0.02
  CVA 26 (0.7) 38 (1.0) 30 (1.6) 94 (1.0) 0.01
  MetS 595 (17.0%) 862 (23.0%) 575 (31.6%) 2032 (22.4%) <0.01
Laboratory parameters
  eGFR (mL/min/1.73 m2) 93.4±13.0 93.9±13.0 96.3±13.0 93.8±13.0 <0.01
  BUN (mg/dL) 14.0±3.6 14.3±3.5 14.7±3.7 14.3±3.6 <0.01
  Creatinine (mg/dL) 0.81±0.16 0.84±0.17 0.86±0.17 0.83±0.17 <0.01
  Haemoglobin (g/L) 134±16 137±16 139±15 136±16 <0.01
  Haematocrit (%) 40.5±4.5 41.2±4.6 41.8±4.4 41.1±4.6 <0.01
  Albumin (g/dL) 4.2±0.3 4.3±0.3 4.2±0.3 4.2±0.3 <0.01
  CRP (mg/L) 0.1 (0.1–0.2) 0.1 (0.1–0.3) 0.2 (0.1–0.3) 0.1 (0.1–0.3) <0.01
  Fasting glucose (mg/dL) 85.7±21.2 87.6±21.2 89.9±22.2 87.4±21.5 <0.01
  Tchol (mg/dL) 187.0±35.5 192.9±35.8 195.4±35.0 191.1±35.7 <0.01
  HDL (mg/dL) 51.1±12.4 49.1±11.6 47.7±11.1 49.6±11.9 <0.01
  TG (mg/dL) 114.0 (80.0–167.0) 126.0 (88.0–183.5) 140.0 (98.0–205.0) 124.0 (87.0–181.0) <0.01
  LDL-C (mg/dL) 111.4±32.2 116.3±33.0 116.5±33.1 114.5±32.8 <0.01
Data are presented as mean±SD, number (%) or median and IQRs.
.BMI, body mass index; BUN, blood urea nitrogen; CHF, congestive heart failure; CRP, C reactive protein; CVA, cerebrovascular accident; 
DBP, diastolic blood pressure; DM, diabetes mellitus; HDL, high-density lipoprotein; HTN, hypertension; LDL-C, low-density lipoprotein 
cholesterol; MAP, mean arterial pressure; MI, myocardial infarction; MetS, metabolic syndrome; SBP, systolic blood pressure; TG, triglyceride; 
Tchol, total cholesterol; eGFR, estimated glomerular filtration rate.
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Table 2 Relationship of sleep quality with snoring frequency
Non-snorer <1 day/week ≥1 day/week Total P value
Insomnia 595 (17.0) 568 (15.2) 294 (16.2) 1457 (16.1) 0.08
Have difficulty falling asleep 464 (13.3) 450 (12.0) 230 (12.6) 1144 (12.6) 0.24
Wake up during the night and not be able to fall 
back sleep
482 (13.8) 462 (12.3) 242 (13.3) 1186 (13.1) 0.15
Wake up too early in the morning 309 (8.8) 331 (8.8) 176 (9.7) 816 (9.0) 0.57
Have irregular sleeping time 2605 (74.6) 2807 (74.9) 1374 (75.5) 6786 (74.9) 0.78
Have the symptoms of restless legs syndrome 377 (10.8) 461 (12.3) 227 (12.5) 1065 (11.8) 0.08
Have experienced periodic limb movements during 
sleep
560 (16.0) 651 (17.4) 323 (17.7) 1534 (16.9) 0.20
Sleep time 6.8±1.4 6.7±1.3 6.7±1.4 6.7±1.4 0.60
ESS score 5.6±4.0 6.2±3.8 7.1±4.2 6.1±4.0 <0.01
EDS 361 (10.3) 462 (12.3) 338 (18.6) 1161 (12.8) <0.01
Data are presented as mean±SD or number (%).
.EDS, excessive daytime sleepiness (ESS ≥11); ESS, Epworth Sleepiness Scale.
Figure 2 Kaplan-Meier curve for development of incident chronic kidney disease according to snoring frequency.
investigations have reported snoring as a risk factor for 
development of CKD. Although snoring is considered 
a symptom of OSA, many subjects who snore do not 
have sleep apnoea.24–26 In addition, EDS and fatigue are 
reported to be related to habitual snoring regardless of 
the apnoea–hypopnoea frequency,27 Also, a recent study 
showed that in men with CKD, those with OSA were not 
more likely to report snoring symptoms.4 Collectively, 
these pieces of evidence suggest a possibility of snoring 
possessing a risk independent from OSA. Studies showing 
that the vibration induced by snoring induces airway 
inflammation, which could subsequently act as a systemic 
inflammatory source, support this possibility.28–30 Another 
point to consider is that the simple measure of self-re-
ported snoring could also be useful as a public health 
screening tool. Given that polysomnography is expensive 
and time consuming, understanding how self-reported 
snoring is related to CKD is clinically significant.
The cause–effect relationship between renal function 
decline and snoring has been debatable, posing a possi-
bility of both diseases being possible risk factors for each 
other. CKD may lead to snoring by various mechanisms, 
including changes in the balance of circulating inter-
leukin-1 beta and tumour necrosis factor-alpha,31 pharyn-
geal stenosis caused by fluid overload and accumulation 
of uraemic toxins.32–34 It is also increasingly recognised 
that snoring promotes loss of kidney function. Animals 
exposed to intermittent hypoxia experienced histopatho-
logical kidney damage through potential mechanisms, 
such as renal hypoxia, hypertension, activation of the 
endothelial dysfunctional sympathetic nervous system and 
increased oxidative stress.35–37 Recently, a cross-sectional 
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Table 3 Relative risk of incident chronic kidney disease according to snoring frequency assessed by Cox regression analysis
Model I Model II Model III
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Non-snorer 1 (reference) 1 (reference) 1 (reference)
<1 day/week 1.20 (1.02 to 1.41) 0.03 1.17 (1.00 to 1.38) 0.05 1.07 (0.96 to 1.18) 0.22
≥1 day/week 1.36 (1.13 to 1.64) <0.01 1.34 (1.11 to 1.62) <0.01 1.23 (1.09 to 1.38) <0.01
Note: model I: adjusted for age and sex. Model II: model I+monthly income, alcohol status and smoking status. Model III: model II+SBP, 
waist:hip ratio, fasting glucose and low-density lipoprotein cholesterol.
.SBP, systolic blood pressure.
analysis of middle-aged and elderly Chinese individuals 
has reported self-reported snoring to be closely associated 
with CKD.38 However, owing to the cross-sectional design 
of their study, it was impossible to infer whether snoring 
increased the risk of CKD or whether the decreased renal 
function induced snoring frequency in this population. 
By prospectively observing the renal outcome of subjects 
with normal renal function, the results of this study could 
better delineate the cause–effect relationship between 
CKD and snoring, suggesting that snoring may increase 
the risk of renal function decline.
The prevalence of MetS was more common among 
snorers compared with non-snorers. This relation-
ship between snoring and metabolic abnormality is in 
concordance with previous reports. Snoring was related 
to elevated blood pressure in pregnant women and in 
patients with diabetes, as well as in the general popula-
tion.39–41 Dyslipidaemia was more prevalent in children 
who snored.42 In addition, snoring was shown to increase 
the risk of development of type 2 diabetes.43 44 Since 
these metabolic derangements as well as MetS itself are 
well-known risk factors for development of CKD, it is 
probable that these snoring-induced metabolic abnor-
malities mediated the renal function decline observed in 
frequent snorers. However, the fact that increased snoring 
frequency was significantly associated with increased risk 
of CKD, even after adjustments were made for metabolic 
factors, suggests the possibility that factors other than 
metabolic derangements may play a role. Further inves-
tigations are required to better elucidate the mediators 
between snoring and renal function decline.
This study has several limitations. First, the use of self-re-
ported questionnaires rather than objective measure-
ments could limit the reliability of the study findings. 
Although the correlation between self-reports of snoring 
and objective measures has not been well evaluated yet, 
self-reported snoring has been reported to be associated 
with various clinical outcomes in several studies.7–9 40 41 44 
This suggests the practical usefulness of such question-
naires in stratifying clinical risks. In addition, objective 
studies such as using microphone recordings, which are 
based on observations recorded in a single night, may not 
reflect the usual sleep status. However, questionnaires that 
ask about average sleep patterns could better reflect the 
usual condition. Second, the fact that self-assessment of 
snoring was validated by bed partners or family members 
could open chance of bias for those who live alone. 
Assuming that those without spouses would most likely 
be living alone, the prevalence of snorers among those 
without spouses was further compared. The proportion 
of snorers among those with spouses were significantly 
higher among those who did not currently live with a 
spouse (online supplementary table 3). However, when 
the current spouse status was included in the adjustment 
model, the significance of the main analysis was main-
tained, suggesting that the abovementioned bias possi-
bility did not considerably affect the relationship between 
snoring and CKD incidence (online supplementary table 
4). Third, distinguishing apnoeic from non-apnoeic 
snoring was not possible. However, knowledge of the risks 
associated with the snoring symptom, whether or not 
associated with OSA, could have clinical importance.
COnCluSIOn
In conclusion, self-reported habitual snoring is a signif-
icant risk factor for development of CKD in individuals 
with normal renal function. Self-reported snoring may be 
an effective and easy early screening method for risk strat-
ification of patients with CKD. However, further investiga-
tions are warranted to conclude whether introduction of 
interventions for snoring could decrease the risk of CKD 
development.
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